Ignite Creation Date:
2024-05-06 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05156788
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-15
First Post:
2021-09-30
Brief Title:
TislelizumabAnti PD-1 Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable Locally Advanced Biliary Tract Cancer
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Organization Data
Organization:
Shanghai Zhongshan Hospital
Class:
OTHER
Study ID:
ZSAB-TransGOLP
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Zhongshan Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None